Proteomics applications in next generation induced pluripotent stem cell models

ABSTRACT

Introduction

Induced pluripotent stem (iPS) cell technology has transformed biomedical research. New opportunities now exist to create new organoids, microtissues, and body-on-a-chip systems for basic biology investigations and clinical translations.

Areas Covered

We discuss the utility of proteomics for attaining an unbiased view into protein expression changes during iPS cell differentiation, cell maturation, and tissue generation. The ability to discover cell-type specific protein markers during the differentiation and maturation of iPS-derived cells has led to new strategies to improve cell production yield and fidelity. In parallel, proteomic characterization of iPS-derived organoids is helping to realize the goal of bridging in vitro and in vivo systems.

Expert Opinions

We discuss some current challenges of proteomics in iPS cell research and future directions, including the integration of proteomic and transcriptomic data for systems-level analysis.

KEYWORDS:

• Induced pluripotent stem cell
• organoids
• mass spectrometry
• proteomics
• secretome

Article highlights

• Opportunities now exist to create organoids and microphysiological systems from human induced pluripotent stem (iPS) cells as the next generation of biomedical reesarch models.

• Application of proteomics techniques can help advance iPS models by providing readouts of cell differentiation yield, purity, and maturity.

• Improvements to both mass spectrometry and non-mass spectrometry methods have drastically improved the proteomic characterization of iPS cell models.

• Continued development of secretome and surfaceome profiling techniques will avail characterization of cell identity and crosstalk at the protein level.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

V Manda. and J Pavelka drafted the manuscript and E Lau revised the manuscript.

Additional information

Funding

This manuscript was funded by NIH award R00-HL144829 and the University of Colorado Translational Research Scholars Program to E Lau. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.